Pear Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Pear Therapeutics's estimated annual revenue is currently $7.7M per year.
- Pear Therapeutics received $64.0M in venture funding in January 2019.
- Pear Therapeutics's estimated revenue per employee is $121,800
- Pear Therapeutics's total funding is $409M.
Employee Data
- Pear Therapeutics has 63 Employees.
- Pear Therapeutics grew their employee count by -81% last year.
Pear Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP, Government Affairs | Reveal Email/Phone |
2 | Director, State Government Affairs | Reveal Email/Phone |
3 | Regional Business Director | Reveal Email/Phone |
4 | Executive Assistant to Chief Medical Officer & Head Clinical Development | Reveal Email/Phone |
5 | Case Manager | Reveal Email/Phone |
6 | Administrative Services Manager/Office Manager | Reveal Email/Phone |
7 | National Partnership & Implementation Manager | Reveal Email/Phone |
8 | Case Manager | Reveal Email/Phone |
9 | Account Manager II | Reveal Email/Phone |
10 | Senior Executive Assistant to CEO and CMO | Reveal Email/Phone |
Pear Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $13.6M | 97 | 13% | N/A | N/A |
#2 | $0.5M | 7 | -50% | N/A | N/A |
#3 | $6.5M | 53 | -25% | $29.3M | N/A |
#4 | $25.9M | 172 | -5% | $45.2M | N/A |
#5 | $8.4M | 67 | 24% | N/A | N/A |
#6 | $77M | 0 | N/A | $866M | N/A |
#7 | $0.3M | 4 | -43% | N/A | N/A |
#8 | $4.4M | 39 | 26% | N/A | N/A |
#9 | $257.9M | 1316 | 10% | N/A | N/A |
#10 | $21.1M | 140 | -16% | $23.3M | N/A |
What Is Pear Therapeutics?
At Pear, our mission is clear: we are pioneers in Prescription Digital Therapeutics, or PDTs. Our cross-functional team operates at the intersection of biotechnology and software technology. Pear discovers, develops, and delivers clinically-validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Every day, we push the boundaries of technology to transform medicine. Pear has a pipeline of products and product candidates across therapeutic areas, including mental health disorders, severe insomnia and multiple sclerosis. Our lead product, reSET®, treats Substance Use Disorder, and was the first PDT to receive marketing authorization from the FDA to treat disease. Pear's second product candidate, reSET-O for the treatment of Opioid Use Disorder, is currently under review by the FDA with Breakthrough Designation. For more information, visit us at www.peartherapeutics.com.
keywords:Biotechnology,Gaming,Healthcare,Human Resources Hr,Information Security,Medical Diagnostics,Mobile,Pharmaceuticals,Security
$409M
Total Funding
63
Number of Employees
$7.7M
Revenue (est)
-81%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Pear Therapeutics News
Pear to host panel discussion with leaders who are paving the way to provide patients access to prescription digital therapeutics for the...
Boston-based Pear's program offers patients seeking treatment for substance use disorder (SUD) or opioid use disorder (OUD) access to a...
In its first year-end financial report after going public via reverse merger last December, Pear Therapeutics inched past nearly all of its predictions for...
What You Should Know: – Pear Therapeutics, the leader in developing and commercializing prescription digital therapeutics to treat serious disease, and Thimble Point Acquisition Corp (Nasdaq: THMA), a special purpose acquisition company (SPAC) whose management team is associated with the Pritzk ...
Other Companies in Boston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.9M | 63 | 5% | N/A |
#2 | $9.8M | 63 | 24% | N/A |
#3 | $11.6M | 63 | -2% | N/A |
#4 | $16.4M | 63 | 3% | N/A |
#5 | $8.3M | 63 | 11% | $0.22M |
Pear Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2015-03-23 | $Undisclosed | Undisclosed | 5AM Ventures | Article |
| 2016-02-05 | $20.0M | Undisclosed | 5AM Ventures | Article |
| 2018-01-03 | $50.0M | B | Temasek | Article |
| 2019-01-07 | $64.0M | C | Temasek | Article |